Selective Androgen Receptor Modulators: A Critical Appraisal

Selective androgen receptor modulators (SARMs) were developed to provide tissue-selective benefits without the side effects of traditional androgens. However, despite promising preclinical results, clinical trials have not demonstrated significant superiority over conventional androgens. SARMs show some efficacy in improving body composition and anti-tumor activity, but these effects are comparable to those of traditional androgens. Concerns about safety, including potential liver toxicity and the lack of estrogenic activity affecting bone health and sexual function, have prevented regulatory approval. The absence of direct comparative trials further complicates the evaluation of their efficacy and safety. Overall, SARMs remain promising but require further research to establish their clinical advantages.